Also known as · Signifor · Signifor LAR
Pasireotide
Somatostatin analog for Cushing disease and acromegaly.
What it is
Pasireotide (Signifor, Signifor LAR) is a multi-receptor somatostatin analog with broader receptor binding than octreotide or lanreotide. It is FDA-approved for Cushing disease (when surgery is not curative) and acromegaly.
Mechanism of action
Broader somatostatin receptor binding (SSTR1, 2, 3, 5) allows effects on cortisol-secreting pituitary tumors that may not respond to standard somatostatin analogs.
Approved indications
- Cushing disease (when surgery is not curative)
- Acromegaly
Why this is out of scope at The Tide
Specialty endocrinology medication for pituitary disorders. Cushing disease and acromegaly require coordinated endocrinology and neurosurgery care.
Where to learn more
Endocrinology, particularly programs specialized in pituitary disorders.
Related peptides
From the same category.
Corticotropin
H.P. Acthar Gel · ACTH
Adrenocorticotropic hormone for infantile spasms and MS relapse.